BRIM8: Vemurafenib in high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
11 Sep 2017
Expert commentary on melanoma immunotherapy latest
Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
11 Sep 2017
Vemurafenib for high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
11 Sep 2017
Dabrafenib plus trametinib for stage III mutant melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
11 Sep 2017
Nivolumab vs ipilimumab for high risk melanoma patients
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
11 Sep 2017
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
11 Sep 2017
The METRIC trial of trametinib, five years on
Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
10 Sep 2017
New strategies in melanoma care
Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
10 Sep 2017
Reduced work ability in cancer survivors
Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway
9 Sep 2017
Problems with survivorship care in Europe
Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy
9 Sep 2017
Underprovision and inequality of specialised cancer care
Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Gree...
9 Sep 2017
